These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27922198)

  • 1. DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.
    Madeddu G; Ortu S; Garrucciu G; Maida I; Melis M; Muredda AA; Mura MS; Babudieri S
    J Med Virol; 2017 Jul; 89(7):1208-1214. PubMed ID: 27922198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
    Madeddu G; Fiore V; Melis M; Ortu S; Mannu F; Muredda AA; Garrucciu G; Bandiera F; Zaru S; Bagella P; Calvisi DF; Babudieri S
    Sci Rep; 2020 Feb; 10(1):2014. PubMed ID: 32029790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
    Fung J; Seto WK; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 Mar; 29(3):428-34. PubMed ID: 24372662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
    Pipili C; Cholongitas E; Papatheodoridis G
    Aliment Pharmacol Ther; 2014 Jan; 39(1):35-46. PubMed ID: 24299322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Singal AK; Fontana RJ
    Aliment Pharmacol Ther; 2012 Mar; 35(6):674-89. PubMed ID: 22257108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
    Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of hepatitis B infection: a brief review.
    Quan DJ
    Nephrol Nurs J; 2008; 35(5):507-10, 534. PubMed ID: 18856082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic myopathy with multiple deletions in mitochondrial DNA associated with long-term use of oral anti-viral drugs for hepatitis B: A case study.
    Fujii T; Takase KI; Honda H; Kawamura N; Yamasaki R; Urata M; Uchiumi T; Iwaki T; Kira JI
    Neuropathology; 2019 Apr; 39(2):162-167. PubMed ID: 30847961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
    Ozaras R; Mete B; Ceylan B; Ozgunes N; Gunduz A; Karaosmanoglu H; Cagatay A; Gokturk K; Erdem L; Kocak F; Senates E; Tabak F
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):774-80. PubMed ID: 24901822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic perspectives in HBV: when to stop NAs.
    Pérez-Cameo C; Pons M; Esteban R
    Liver Int; 2014 Feb; 34 Suppl 1():146-53. PubMed ID: 24373092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
    Buti M
    Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC; He LL; Chen Q
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
    Yang S; Xing H; Wang Q; Wang X; Liu S; Cheng J
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():24. PubMed ID: 27079793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy.
    Li XY; You X; Jie YS; Lin GL; Wu YK; Huang MX; Zhang M; Li ZY; Xie DY; Gao ZL; Chong YT
    Am J Ther; 2017 May; 24(3):e250-e258. PubMed ID: 25923228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.